KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income - MinorityNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Revenue (2016 - 2026)

Teva Pharmaceutical Industries filings provide 18 years of Revenue readings, the most recent being $4.0 billion for Q1 2026.

  • On a quarterly basis, Revenue rose 2.34% to $4.0 billion in Q1 2026 year-over-year; TTM through Mar 2026 was $17.3 billion, a 13.49% increase, with the full-year FY2025 number at $17.3 billion, up 4.32% from a year prior.
  • Revenue hit $4.0 billion in Q1 2026 for Teva Pharmaceutical Industries, down from $4.7 billion in the prior quarter.
  • In the past five years, Revenue ranged from a high of $4.7 billion in Q4 2025 to a low of $2.9 billion in Q4 2024.
  • Median Revenue over the past 5 years was $3.9 billion (2022), compared with a mean of $4.0 billion.
  • Biggest five-year swings in Revenue: tumbled 34.93% in 2024 and later soared 62.45% in 2025.
  • Teva Pharmaceutical Industries' Revenue stood at $3.9 billion in 2022, then increased by 14.75% to $4.5 billion in 2023, then tumbled by 34.93% to $2.9 billion in 2024, then skyrocketed by 62.45% to $4.7 billion in 2025, then dropped by 15.47% to $4.0 billion in 2026.
  • The last three reported values for Revenue were $4.0 billion (Q1 2026), $4.7 billion (Q4 2025), and $4.5 billion (Q3 2025) per Business Quant data.